Reassuringly, only a very small percentage of people with T2D experienced hypoglycaemia in the phase 2 trial which included people on lifestyle interventions or metformin; however, the TRANSCEND-T2D-3 study which includes people with T2D and CKD on basal insulin, will provide further insight into hypoglycaemia risk in high-risk populations. Here, INS is linked to Hypoglycemia.